Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31374417 | 0.98 | KDM4E (0.42) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL409030 | 0.82 | KDM4E (0.55) | KDM4ELMNACCR1CCR5CCR8 | |
| Phosphine SCHEMBL17979775 | 0.80 | KDM4E (0.53) | KDM4ELMNACCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL28670387 | 0.80 | KDM4E (0.53) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28077971 | 0.79 | MEN1 (0.41) | KDM4ELMNASMN1; SMN2NPC1ALDH1A1 | |
| Ethylene SCHEMBL27741856 | 0.78 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL8932281 | 0.74 | GOT1 (0.31) | — | |
| SCHEMBL12129562 | 0.74 | KDM4E (0.58) | KDM4ELMNACCR1CCR5CCR8 | |
| Formaldehyde SCHEMBL28375942 | 0.73 | — | — | |
| SCHEMBL207642 | 0.72 | HAO1 (0.53) | KDM4ECYP1A2LTA4HHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661509-A | Pyridine oxazazole sulfur sulfone compound and preparation method and application thereof | 湖南省农业科学院 | 2025-03-21 | — | — | CN | claimed |
| CN-119661509-A | Pyridine oxazazole sulfur sulfone compound and preparation method and application thereof | 湖南省农业科学院 | 2025-03-21 | — | — | CN | disclosed |
| CN-114867723-B | Salt forms, crystal forms and pharmaceutical compositions of pyridyloxy-pyrazoles as TGF-beta R1 inhibitors | 江苏奥赛康药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-114867723-B | Salt forms, crystal forms and pharmaceutical compositions of pyridyloxy-pyrazoles as TGF-beta R1 inhibitors | 江苏奥赛康药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-114867723-A | Salt form, crystal form and pharmaceutical composition of pyridyloxy pyrazole compound serving as TGF-beta R1 inhibitor | 江苏奥赛康药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114867723-A | Salt form, crystal form and pharmaceutical composition of pyridyloxy pyrazole compound serving as TGF-beta R1 inhibitor | 江苏奥赛康药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022017208-A1 | SALT FORM AND CRYSTAL FORM OF PYRIDYLOXY PYRAZOLE COMPOUND AS TGF-βR1 INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF | 江苏奥赛康药业有限公司 | 2022-01-27 | — | — | WO | disclosed |
| US-9782407-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| EP-1848430-B1 | NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-08-02 | — | — | EP | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9040558-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-05-26 | — | — | US | disclosed |
| CN-102197031-A | Substituted 5-aminopyrazoles and use thereof | BAYER SCHERING PHARMA AG | 2011-09-21 | — | — | CN | disclosed |
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020366-A1 | AZABICYCLIC SUBSTITUTED 5-AMINOPYRAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216866-A1 | SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, MTTP | KDM4E 1933/4885LMNA 851/4885CCR1 3725/4885 |
| US-20060178514-A1 | Novel benzylamine derivatives as CETP inhibitors | CETP, NPC1, LIPC | KDM4E 1107/4885LMNA 344/4885CCR1 3881/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | KDM4E 2516/4885LMNA 4322/4885CCR1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.